Global Opioid Use Disorder Market

Opioid Use Disorder Comprehensive Study by Application (Moderate Pain Treatment, Severe Pain Treatment), Drug (Buprenorphine (Bunavail) Players and Region - Global Market Outlook to 2026

Opioid Use Disorder Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Opioid Use Disorder Market Overview:
Opioid Use Disorder (OUD) is a long-term illness characterised by compulsive, prolonged, and repetitive opioid self-administration. Patients with OUD are divided into two groups: those who are addicted to non-medical opioids and those who are addicted to medical opioids. OUD cannot be explained by a single cause, but the patient is influenced by a mixture of environmental and genetic factors.

Growth Drivers
  • Increasing intensity of opioid epidemic
  • Strong pipeline of pharmaceuticals and expected commercialization of the products


Roadblocks
  • Complications associated with the reimbursement scenarios for addiction therapies

Opportunities
  • Growing government initiatives to combat the crisis
  • Growth potential in developing countries

Challenges
  • Lack of awareness


Competitive Landscape:
Companies operating in the global risedronate sodiums market should focus on mergers & acquisitions to improve their market share and overall position. Product launches, research, and expansion of the existing product portfolio are some of the other strategies that should be considered to gain ground in the current risedronate sodiums market during the assessment period.
Some of the key players profiled in the report are Indivior (United States), Alkermes (Ireland), Titan Pharmaceuticals (United States), Hikma Pharmaceuticals (United Kingdom), Teva Pharmaceuticals (Israel), MediciNova (United States), Orexo (Sweden), Camurus (Sweden) and Omeros (United States). Analyst at AMA Research see Global Players to retain maximum share of Global Opioid Use Disorder market by 2026. Considering Market by Drug, the sub-segment i.e. Buprenorphine (Bunavail will boost the Opioid Use Disorder market.

Latest Market Insights:
In Feb 2019, Titan Pharmaceuticals, Inc. announced that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.

In Jan 2019, Novartis AG’s business division Sandoz Inc. along with Pear Therapeutics, Inc. announced that they had launched “reSET-O” commercially for patients suffering from opioid use.

What Can be Explored with the Opioid Use Disorder Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Opioid Use Disorder Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Opioid Use Disorder
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Opioid Use Disorder market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Opioid Use Disorder market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planner, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Moderate Pain Treatment
  • Severe Pain Treatment
By Drug
  • Buprenorphine (Bunavail

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing intensity of opioid epidemic
      • 3.2.2. Strong pipeline of pharmaceuticals and expected commercialization of the products
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Opioid Use Disorder, by Application, Drug and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Opioid Use Disorder (Value)
      • 5.2.1. Global Opioid Use Disorder by: Application (Value)
        • 5.2.1.1. Moderate Pain Treatment
        • 5.2.1.2. Severe Pain Treatment
      • 5.2.2. Global Opioid Use Disorder by: Drug (Value)
        • 5.2.2.1. Buprenorphine (Bunavail
      • 5.2.3. Global Opioid Use Disorder Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Opioid Use Disorder: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Indivior (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alkermes (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Titan Pharmaceuticals (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MediciNova (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Orexo (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Camurus (Sweden)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Omeros (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Opioid Use Disorder Sale, by Application, Drug and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Opioid Use Disorder (Value)
      • 7.2.1. Global Opioid Use Disorder by: Application (Value)
        • 7.2.1.1. Moderate Pain Treatment
        • 7.2.1.2. Severe Pain Treatment
      • 7.2.2. Global Opioid Use Disorder by: Drug (Value)
        • 7.2.2.1. Buprenorphine (Bunavail
      • 7.2.3. Global Opioid Use Disorder Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Opioid Use Disorder: by Application(USD Million)
  • Table 2. Opioid Use Disorder Moderate Pain Treatment , by Region USD Million (2015-2020)
  • Table 3. Opioid Use Disorder Severe Pain Treatment , by Region USD Million (2015-2020)
  • Table 4. Opioid Use Disorder: by Drug(USD Million)
  • Table 5. Opioid Use Disorder Buprenorphine (Bunavail , by Region USD Million (2015-2020)
  • Table 6. South America Opioid Use Disorder, by Country USD Million (2015-2020)
  • Table 7. South America Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 8. South America Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 9. Brazil Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 10. Brazil Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 11. Argentina Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 12. Argentina Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 13. Rest of South America Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 14. Rest of South America Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 15. Asia Pacific Opioid Use Disorder, by Country USD Million (2015-2020)
  • Table 16. Asia Pacific Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 17. Asia Pacific Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 18. China Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 19. China Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 20. Japan Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 21. Japan Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 22. India Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 23. India Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 24. South Korea Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 25. South Korea Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 26. Taiwan Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 27. Taiwan Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 28. Australia Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 29. Australia Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 30. Rest of Asia-Pacific Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 31. Rest of Asia-Pacific Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 32. Europe Opioid Use Disorder, by Country USD Million (2015-2020)
  • Table 33. Europe Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 34. Europe Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 35. Germany Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 36. Germany Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 37. France Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 38. France Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 39. Italy Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 40. Italy Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 41. United Kingdom Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 42. United Kingdom Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 43. Netherlands Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 44. Netherlands Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 45. Rest of Europe Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 46. Rest of Europe Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 47. MEA Opioid Use Disorder, by Country USD Million (2015-2020)
  • Table 48. MEA Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 49. MEA Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 50. Middle East Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 51. Middle East Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 52. Africa Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 53. Africa Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 54. North America Opioid Use Disorder, by Country USD Million (2015-2020)
  • Table 55. North America Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 56. North America Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 57. United States Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 58. United States Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 59. Canada Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 60. Canada Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 61. Mexico Opioid Use Disorder, by Application USD Million (2015-2020)
  • Table 62. Mexico Opioid Use Disorder, by Drug USD Million (2015-2020)
  • Table 63. Company Basic Information, Sales Area and Its Competitors
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Opioid Use Disorder: by Application(USD Million)
  • Table 73. Opioid Use Disorder Moderate Pain Treatment , by Region USD Million (2021-2026)
  • Table 74. Opioid Use Disorder Severe Pain Treatment , by Region USD Million (2021-2026)
  • Table 75. Opioid Use Disorder: by Drug(USD Million)
  • Table 76. Opioid Use Disorder Buprenorphine (Bunavail , by Region USD Million (2021-2026)
  • Table 77. South America Opioid Use Disorder, by Country USD Million (2021-2026)
  • Table 78. South America Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 79. South America Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 80. Brazil Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 81. Brazil Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 82. Argentina Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 83. Argentina Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 84. Rest of South America Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 85. Rest of South America Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 86. Asia Pacific Opioid Use Disorder, by Country USD Million (2021-2026)
  • Table 87. Asia Pacific Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 88. Asia Pacific Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 89. China Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 90. China Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 91. Japan Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 92. Japan Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 93. India Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 94. India Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 95. South Korea Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 96. South Korea Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 97. Taiwan Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 98. Taiwan Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 99. Australia Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 100. Australia Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 101. Rest of Asia-Pacific Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 102. Rest of Asia-Pacific Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 103. Europe Opioid Use Disorder, by Country USD Million (2021-2026)
  • Table 104. Europe Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 105. Europe Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 106. Germany Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 107. Germany Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 108. France Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 109. France Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 110. Italy Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 111. Italy Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 112. United Kingdom Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 113. United Kingdom Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 114. Netherlands Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 115. Netherlands Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 116. Rest of Europe Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 117. Rest of Europe Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 118. MEA Opioid Use Disorder, by Country USD Million (2021-2026)
  • Table 119. MEA Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 120. MEA Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 121. Middle East Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 122. Middle East Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 123. Africa Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 124. Africa Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 125. North America Opioid Use Disorder, by Country USD Million (2021-2026)
  • Table 126. North America Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 127. North America Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 128. United States Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 129. United States Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 130. Canada Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 131. Canada Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 132. Mexico Opioid Use Disorder, by Application USD Million (2021-2026)
  • Table 133. Mexico Opioid Use Disorder, by Drug USD Million (2021-2026)
  • Table 134. Research Programs/Design for This Report
  • Table 135. Key Data Information from Secondary Sources
  • Table 136. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Opioid Use Disorder: by Application USD Million (2015-2020)
  • Figure 5. Global Opioid Use Disorder: by Drug USD Million (2015-2020)
  • Figure 6. South America Opioid Use Disorder Share (%), by Country
  • Figure 7. Asia Pacific Opioid Use Disorder Share (%), by Country
  • Figure 8. Europe Opioid Use Disorder Share (%), by Country
  • Figure 9. MEA Opioid Use Disorder Share (%), by Country
  • Figure 10. North America Opioid Use Disorder Share (%), by Country
  • Figure 11. Global Opioid Use Disorder share by Players 2020 (%)
  • Figure 12. Global Opioid Use Disorder share by Players (Top 3) 2020(%)
  • Figure 13. Global Opioid Use Disorder share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Indivior (United States) Revenue, Net Income and Gross profit
  • Figure 16. Indivior (United States) Revenue: by Geography 2020
  • Figure 17. Alkermes (Ireland) Revenue, Net Income and Gross profit
  • Figure 18. Alkermes (Ireland) Revenue: by Geography 2020
  • Figure 19. Titan Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 20. Titan Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 21. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 25. MediciNova (United States) Revenue, Net Income and Gross profit
  • Figure 26. MediciNova (United States) Revenue: by Geography 2020
  • Figure 27. Orexo (Sweden) Revenue, Net Income and Gross profit
  • Figure 28. Orexo (Sweden) Revenue: by Geography 2020
  • Figure 29. Camurus (Sweden) Revenue, Net Income and Gross profit
  • Figure 30. Camurus (Sweden) Revenue: by Geography 2020
  • Figure 31. Omeros (United States) Revenue, Net Income and Gross profit
  • Figure 32. Omeros (United States) Revenue: by Geography 2020
  • Figure 33. Global Opioid Use Disorder: by Application USD Million (2021-2026)
  • Figure 34. Global Opioid Use Disorder: by Drug USD Million (2021-2026)
  • Figure 35. South America Opioid Use Disorder Share (%), by Country
  • Figure 36. Asia Pacific Opioid Use Disorder Share (%), by Country
  • Figure 37. Europe Opioid Use Disorder Share (%), by Country
  • Figure 38. MEA Opioid Use Disorder Share (%), by Country
  • Figure 39. North America Opioid Use Disorder Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Indivior (United States)
  • Alkermes (Ireland)
  • Titan Pharmaceuticals (United States)
  • Hikma Pharmaceuticals (United Kingdom)
  • Teva Pharmaceuticals (Israel)
  • MediciNova (United States)
  • Orexo (Sweden)
  • Camurus (Sweden)
  • Omeros (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 243 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Opioid Use Disorder Market Quantitative research analysis
Global Opioid Use Disorder Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Opioid Use Disorder Market Report?

Have a Query? Click Here

Other Related Reports

Esophageal Cancer Drugs Comprehensive Study by Type (Carboplatin, Oxaliplatin, Cisplatin, Paclitaxel), Application (Hospitals, Cancer Clinics), End- User (Men, Women) Players and Region - Global Mark...
$ 3500
Antirheumatics Pharmaceutical Comprehensive Study by Type (Non-Steroidal Anti-Inflammatory Drugs, Steroidal Anti-Inflammatory Drugs, Slow Acting Drug, Immunological Preparation), Application (Pharmac...
$ 3750
Bronchiectasis Drugs Comprehensive Study by Type (Antibiotics, Expectorants, Beta-Agonists, Inhaled Corticosteroids, Others), Indication (Cylindrical Bronchiectasis, Varicose Bronchiectasis, Cystic B...
$ 3450
Blepharitis Comprehensive Study by Type (Anterior Blepharitis, Posterior Blepharitis, Mixed Blepharitis), Application (Specialty centers, Hospitals, Others), Treatment (Eye cleansers, Artificial tear...
$ 3650
Biologics Fill and Finish Services Comprehensive Study by Type (Liquid, Lyophilized), Application (Preclinical, Clinical, Commercial), Organization Size (Small-sized, Mid -sized, Large / very large),...
$ 3750
Thyroid Disorder Comprehensive Study by Type (Hypothyroidism, Hyperthyroidism, Goiter, Thyroid nodules, Thyroid cancer), Treatment (Homeopathic Treatment, Ayurvedic Treatment, Other (Allelopathy)), E...
$ 3750